(RNA) Avidity Biosciences - Overview
Stock: RNA Therapeutics, Antibody Conjugates, Muscle Dystrophy, Cardiomyopathy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 3.53% |
| Relative Tail Risk | -10.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.27 |
| Alpha | 94.37 |
| Character TTM | |
|---|---|
| Beta | 1.017 |
| Beta Downside | 0.831 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.01% |
| CAGR/Max DD | 0.59 |
Description: RNA Avidity Biosciences January 10, 2026
Avidity Biosciences (NASDAQ:RNA) is a San Diego-based biopharma that develops antibody-oligonucleotide conjugates (AOCs), marrying monoclonal-antibody targeting precision with RNA-based therapeutic activity to address disease mechanisms that have been out of reach for conventional drugs.
The firm’s current pipeline includes three registrational-stage programs: Delpacibart etedesiran (Phase 3 for myotonic dystrophy type 1), Delpacibart braxlosiran (Phase 1/2 for facioscapulohumeral muscular dystrophy) and Delpacibart zotadirsen (Phase 2 EXPLORE44 open-label extension for Duchenne muscular dystrophy). In addition, Avidity is pursuing rare-genetic cardiomyopathy candidates-AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for PRKAG2 syndrome.
As of the latest quarterly filing (Q3 2024), the company reported roughly $260 million of cash and marketable securities, giving it an estimated runway of 12-18 months without additional financing. The RNA-therapeutics sector is projected to grow at a ~12 % CAGR through 2030, driven by expanding acceptance of oligonucleotide modalities and increasing payer willingness to reimburse rare-disease treatments. Avidity’s 2023 $115 million private placement and a strategic collaboration with Roche on AOC technology provide both capital and validation, but the firm remains highly dependent on the success of its lead myotonic dystrophy trial to achieve meaningful revenue upside.
For a deeper, data-driven look at RNA’s valuation dynamics, you may find ValueRay’s analytical dashboard worth a quick glance.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -549.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -16.41 > 1.0 |
| NWC/Revenue: 8607 % < 20% (prev 15.1k%; Δ -6521 % < -1%) |
| CFO/TA -0.27 > 3% & CFO -580.5m > Net Income -549.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (137.9m) vs 12m ago 11.77% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.11% > 50% (prev 0.62%; Δ 0.49% > 0%) |
| Interest Coverage Ratio: -12.38 > 6 (EBITDA TTM -594.7m / Interest Expense TTM -48.3m) |
Altman Z'' -4.33
| A: 0.84 (Total Current Assets 1.97b - Total Current Liabilities 169.9m) / Total Assets 2.13b |
| B: -0.63 (Retained Earnings -1.34b / Total Assets 2.13b) |
| C: -0.32 (EBIT TTM -598.1m / Avg Total Assets 1.89b) |
| D: -5.40 (Book Value of Equity -1.34b / Total Liabilities 247.9m) |
| Altman-Z'' Score: -4.33 = D |
Beneish M 1.00
| DSRI: 0.38 (Receivables 15.0m/19.2m, Revenue 20.9m/10.1m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 23.18 (AQ_t 0.04 / AQ_t-1 0.00) |
| SGI: 2.06 (Revenue 20.9m / 10.1m) |
| TATA: 0.01 (NI -549.8m - CFO -580.5m) / TA 2.13b) |
| Beneish M-Score: 10.39 (Cap -4..+1) = D |
What is the price of RNA shares?
Over the past week, the price has changed by +0.45%, over one month by +0.90%, over three months by +4.47% and over the past year by +107.63%.
Is RNA a buy, sell or hold?
- StrongBuy: 9
- Buy: 6
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.6 | 2.4% |
| Analysts Target Price | 74.6 | 2.4% |
| ValueRay Target Price | 94.7 | 29.9% |
RNA Fundamental Data Overview February 07, 2026
P/B = 5.9547
Revenue TTM = 20.9m USD
EBIT TTM = -598.1m USD
EBITDA TTM = -594.7m USD
Long Term Debt = 50.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.97m USD (from shortTermDebt, last quarter)
Debt = 50.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -300.2m USD (from netDebt column, last quarter)
Enterprise Value = 9.42b USD (11.25b + Debt 50.0m - CCE 1.88b)
Interest Coverage Ratio = -12.38 (Ebit TTM -598.1m / Interest Expense TTM -48.3m)
EV/FCF = -15.83x (Enterprise Value 9.42b / FCF TTM -595.4m)
FCF Yield = -6.32% (FCF TTM -595.4m / Enterprise Value 9.42b)
FCF Margin = -2853 % (FCF TTM -595.4m / Revenue TTM 20.9m)
Net Margin = -2635 % (Net Income TTM -549.8m / Revenue TTM 20.9m)
Gross Margin = unknown ((Revenue TTM 20.9m - Cost of Revenue TTM 138.9m) / Revenue TTM)
Tobins Q-Ratio = 4.42 (Enterprise Value 9.42b / Total Assets 2.13b)
Interest Expense / Debt = 0.78% (Interest Expense 391.0k / Debt 50.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -472.5m (EBIT -598.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.57 (Total Current Assets 1.97b / Total Current Liabilities 169.9m)
Debt / Equity = 0.03 (Debt 50.0m / totalStockholderEquity, last quarter 1.89b)
Debt / EBITDA = 0.50 (negative EBITDA) (Net Debt -300.2m / EBITDA -594.7m)
Debt / FCF = 0.50 (negative FCF - burning cash) (Net Debt -300.2m / FCF TTM -595.4m)
Total Stockholder Equity = 1.46b (last 4 quarters mean from totalStockholderEquity)
RoA = -29.13% (Net Income -549.8m / Total Assets 2.13b)
RoE = -37.70% (Net Income TTM -549.8m / Total Stockholder Equity 1.46b)
RoCE = -39.66% (EBIT -598.1m / Capital Employed (Equity 1.46b + L.T.Debt 50.0m))
RoIC = -32.40% (negative operating profit) (NOPAT -472.5m / Invested Capital 1.46b)
WACC = 9.62% (E(11.25b)/V(11.30b) * Re(9.66%) + D(50.0m)/V(11.30b) * Rd(0.78%) * (1-Tc(0.21)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 34.65%
Fair Price DCF = unknown (Cash Flow -595.4m)
EPS Correlation: 10.83 | EPS CAGR: 22.05% | SUE: 4.0 | # QB: 1
Revenue Correlation: 47.56 | Revenue CAGR: 66.31% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-1.28 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=-4.92 | Chg30d=-0.030 | Revisions Net=-1 | Growth EPS=-9.5% | Growth Revenue=+5.3%